A Pilot Study of Pembrolizumab Monotherapy or Pembrolizumab Based Combination Therapy in Patients With Previously Treated Advanced Gastroesophageal Adenocarcinoma

Trial Profile

A Pilot Study of Pembrolizumab Monotherapy or Pembrolizumab Based Combination Therapy in Patients With Previously Treated Advanced Gastroesophageal Adenocarcinoma

Recruiting
Phase of Trial: Phase 0

Latest Information Update: 16 Feb 2018

At a glance

  • Drugs Pembrolizumab (Primary) ; Ramucirumab
  • Indications Adenocarcinoma; Gastric cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 Feb 2018 Planned End Date changed from 1 Mar 2022 to 1 Feb 2022.
    • 12 Feb 2018 Planned primary completion date changed from 1 Mar 2022 to 1 Feb 2022.
    • 12 Feb 2018 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top